OurMind Lands €2.1M as 80+ Dutch Doctors Join Its Cap Table

Amsterdam AI healthtech OurMind has closed a €2.1 million funding round. More than 80 Dutch GPs and medical specialists have joined the cap table alongside lead investor 4impact capital, the lead funder of the round announced on 11 June 2026. The seed follows the company’s founding in 2024 by a team that includes former orthopaedic surgeon Paul Koning, with the company’s own users funding the round from the start.

More than 80 GPs and medical specialists have invested in OurMind since its earliest days, a structure the company describes as deliberate. Those clinicians are shareholders who help direct the product roadmap. Koning and his co-founders built the platform around that feedback loop, with the company’s own about page noting that the doctors investing in the company are themselves the use case. The capital will be used to scale the platform into more Dutch hospitals and general practices.

The Clinicians Who Put In Their Own Money

OurMind did not start with a product. The founders started with phone calls, asking care professionals what they actually needed from AI, and the company says the roadmap is still shaped by the clinicians using the product every day. More than 80 clinicians are now investors in the business, and the company says that number is climbing as new GPs and specialists put in their own money. Koning, who trained as an orthopaedic surgeon before founding the company, has framed that feedback loop as the foundation of how OurMind gets built. In the company’s own framing, OurMind is built by care professionals, for care professionals, and that statement describes how the company actually operates.

The result is a product that has been pulled into clinical settings faster than a typical Dutch healthtech seed. Today, more than 300 general practices and 14 hospitals use the platform, a footprint the company says is unusual for a startup barely two years old. The cap table mirrors the customer base. When a doctor on the cap table tells OurMind’s team what is broken, the company has said, the team does not have to imagine the use case.

That working day is exactly what the platform is built to change. Bart Driesen, cardiologist and CMIO at Maasziekenhuis Pantein, said five years ago there was not really a sense of necessity yet, but the waiting list at his hospital now runs to 150 patients with a new referral who cannot even get an appointment right away. In his view, that is simply not sustainable.

Ultimately, you need an AI layer across the entire hospital. Doctors currently spend two to three hours a day preparing consultations, often at home in the evening. If AI can largely take that over, it changes our working day.

The Two-Hour Documentation Tax on Every Working Day

The two-to-three-hour tax is widespread, Driesen has suggested. The same workload shows up in burnout data collected by Dutch medical associations, with a quarter of young doctors in the Netherlands showing burnout symptoms according to a study by De Jonge Specialist. The structural pressure behind that figure is stark, with waiting lists growing, doctors working overtime, and administrative pressure continuing to mount. A separate forecast from the Scientific Council for Government Policy, the WRR, expects that one in four Dutch workers will be needed in healthcare by 2040, up from one in seven today.

That data has set the case for accelerating adoption of generative AI in clinical settings, and the case is overdue. The platform is positioned as a personal AI layer that grows with each clinician, handling documentation and routine work before, during, and after consultations. OurMind’s own description of its platform and cap table sets out the company’s view that AI is finally good enough to take real work off clinicians’ hands. What comes next, the company argues, is a shift in which care professionals stop being passengers and start designing how care gets delivered at scale. Koning has framed the moment as the right one for hospitals to commit, because the alternative is to watch clinicians leave the profession.

The structural argument for scaling is stark. Waiting lists have grown past the point of being absorbed by staffing alone. Koning has framed the company’s deeper work as building the kind of ambient capture that lets clinicians stop being typists and start being clinicians. The cost of doing nothing, Koning argues, is now far greater than the cost of investing in AI support, and the same numbers are also why 4impact, which has not previously invested in healthtech, is leading the round.

The shape of the problem is clear. What OurMind, 4impact, and the company’s clinical partners have published is a workforce under structural strain and a toolset that clinicians themselves have already begun funding. Doctors who do the work are now also bankrolling the attempt to automate parts of it.

• €2.1M raised in the seed round
• More than 80 GPs and medical specialists on the cap table
• 300+ general practices and 14 hospitals use the platform
• A quarter of young doctors in the Netherlands show burnout symptoms
• 1 in 7 Dutch workers in healthcare today, with WRR forecasting 1 in 4 by 2040

A Software-First Fund Steps Into Healthtech

It is a first for 4impact. The Dutch venture firm typically invests in software companies addressing societal themes such as energy, sustainability, and digitalisation, and OurMind is the first healthtech investment on its books. The company is also the fund’s first move into a vertical where the buyer is a public hospital rather than a private sector customer. Straatman said the timing was overdue, telling readers in his firm’s announcement that AI in healthcare has moved beyond the curiosity phase, with hospitals showing a willingness to adopt this kind of technology that the firm did not see two years ago.

4impact partner Victor Straatman said the structure is also unusual. The fund, he said in the lead investor’s own announcement, is a venture capital investor, meaning everything OurMind earns stays in the company for further development. 4impact capital’s own announcement of the OurMind seed round makes the point that the firm plans to remain actively involved, contributing capital, network, and strategic guidance to the company. The deal also carries institutional backing from Invest-NL and the European Union under the InvestEU Fund, layers of public support that are unusual for a Dutch seed. The conviction, he has suggested, fits a wider European pattern in which homegrown clinical-AI founders are building for local markets, with Tandem Health’s CEO on competing with US AI rivals making a similar case.

From 4impact’s perspective, the bet is infrastructure. The team is backing the assumption that ambient AI assistants, the kind that listen, summarise, and write up, will become a default layer in Dutch hospitals within the next few years. OurMind’s cap table, with clinicians as shareholders, is being built to deliver on that assumption.

From Notes to a Single AI Layer

OurMind’s product has evolved in line with that assumption. The company started with a single product, an AI scribe called Notes that turns consultation conversations into structured medical documentation. Today, Notes is used in more than 300 general practices and 14 hospitals across the Netherlands, a footprint the company says is unusual for a startup barely two years old. The roadmap from there is to take the same ambient capture and apply it to the rest of the working day, including pre-visit preparation, in-visit prompts, and post-visit administrative follow-up.

The platform that sits behind Notes is now being expanded in scope. Koning has framed the longer-term goal as a single AI layer across the entire hospital, one that handles intake, consultation, and follow-up in a single workflow. Point tools bolted onto an electronic health record are not the model, and the team has been clear that the company is not chasing that approach.

• Notes: AI scribe that turns consultation conversations into structured medical documentation
• Consultation preparation: review of patient history and relevant material before a visit
• Administrative support: drafting and structuring of clinical notes, reports, and summaries
• Patient communication: drafting messages and follow-up correspondence
• Compliance: built to GDPR, ISO 27001, and NEN 7510 from day one

The full ambition is to move from one scribe product to a platform that knows the patient, the workflow, and the clinician, all in one layer. Koning has been clear that the company is not chasing a generic AI assistant, and the platform is purpose-built for clinical work. AI that turns operating-room video into operative notes is now a parallel pattern in surgical settings, showing the ambient-capture thesis is being tested across more than one European clinical workflow. OurMind’s own about page describes the end state as one where a cardiologist opens her clinic with referrals triaged overnight and her next patient’s intake already done. That is the bet.

The shape is set by the cap table. When a doctor on the cap table tells OurMind’s team what is broken, the company has said, the team does not have to imagine the use case. Koning has framed the roadmap as a direct response to what the clinicians investing in the company actually need, not what a generic AI vendor would build. That feedback loop is now being tested at scale, with the 14 hospitals and 300 general practices already on the platform using the product every day.

The 2040 Workforce Math

The case for urgency sits in the workforce numbers. Today, one in seven workers in the Netherlands is employed in healthcare, a proportion the company and its investors call unsustainable. The Scientific Council for Government Policy, the WRR, forecasts that by 2040, one in four workers will be needed in the healthcare sector just to keep current service levels running. The WRR’s own English page on future-proof Dutch healthcare lays out the demographic math behind that projection. Hospital boards, Koning argues, are now starting to realise that the costs of doing nothing, from staff absence to lengthening waiting lists to clinicians leaving the profession, are far greater than the cost of investing in AI support now.

That pressure is real. Koning has argued across his comments on the deal that doing nothing is the more expensive option, because the bill shows up later in staff absence, waiting lists, and clinicians leaving the profession. The platform’s adoption, with 14 hospitals and more than 300 general practices already running it, is the early evidence the company points to. The test, in Koning’s framing, is whether the company can scale fast enough to keep delivering good care with the same number of people.

What the €2.1M Buys

That argument is also what the new money is for. Koning has said the €2.1M will let OurMind scale up and expand its platform so it can meet, and continue to meet, demand from hospitals. The company plans to broaden the product line beyond Notes into consultation preparation, administrative support, and patient communication, and to push the platform deeper into general practices.

Ultimately, this is not about AI, but about how we can continue to deliver good care with the same number of people.

He framed it that way. Paul Koning, founder of OurMind and a former orthopaedic surgeon, said when the deal was announced that doing nothing was the more expensive option. OurMind has signalled that the capital will fund team growth, deeper integration with Dutch electronic health record systems, and continued expansion of the customer base, with compliance already part of the pitch. The platform is GDPR compliant and certified to ISO 27001 and NEN 7510, and the longer-term build is meant to meet the European Medical Device Regulation and the EU AI Act, two frameworks that have moved from background noise to procurement gating factors in Dutch hospital tenders.

It is safe to plug in. OurMind’s cap table, with more than 80 of its own users as shareholders, is the mechanism through which the company is trying to prove that the AI layer can be deployed without disrupting the existing clinical workflow. Whether that model can scale fast enough to keep up with the workforce numbers WRR has forecast is the test Koning has set for the platform in the years ahead.